menu
Catharanthine Market to Reach $942 Million by 2026
Catharanthine Market to Reach $942 Million by 2026
Catharanthine Market size is forecast to reach US$942 million by 2026, and is growing at a CAGR of 3.6% during 2021-2026. Catharanthine is an organic heteropentacyclic compound and monoterpenoid indole alkaloid produced by the medicinal plant Catharanthus roseus via strictosi forecast to reach US$942 million by 2026

Catharanthine Market size is forecast to reach US$942 million by 2026, and is growing at a CAGR of 3.6% during 2021-2026. Catharanthine is an organic heteropentacyclic compound and monoterpenoid indole alkaloid produced by the medicinal plant Catharanthus roseus via strictosi forecast to reach US$942 million by 2026, and is growing at a CAGR of 3.6% during dine. It is a bridged compound, an organic heteropentacyclic compound, a methyl ester, a monoterpenoid indole alkaloid, a tertiary amino compound and an alkaloid ester. Catharanthine is one of the two precursors that form vinblastine, the other being vindoline. Vinblastine (VBL), is a chemotherapy medication, typically used with other medications, to treat a number of types of cancer. This includes Hodgkin's lymphoma, non-small cell lung cancer, bladder cancer, brain cancer, melanoma, and testicular cancer. Catharanthine sulfate is a vinblastine-type alkaloid precursor with antitumor activity while Catharanthine tartrate is the starting material for the synthesis of the antitumor drugs. Catharanthine finds a number of application in the healthcare and pharmaceutical industry. Hence a growth in the market is predicted.

COVID-19 Impact

Due to the COVID-19 pandemic, Pharmaceutical Industry was majorly impacted. Most of the raw material manufacturing plants were shut down, which declined the production of catharanthine and the medications derived from catharanthine. Due to countrywide Lockdown and cross border Import Export restrictions, supply chain disrupted. Raw material delays or non-arrival, disrupted financial flows, and rising absenteeism among production line staff, OEMs have been forced to function at zero or partial capacity, resulting in lower demand and consumption for catheranthine in 2019-2020. However, due to the burden of cancer incidence and mortality is rapidly growing worldwide, the demand for catheranthine will grow and recover the market with minor economical disruption in the forecast period.

Request for Sample Report  @ https://www.industryarc.com/pdfdownload.php?id=15679

Report Price: $ 4500 (Single User License)

Catharanthine Market Segment Analysis – By Type

Catharanthine sulphate segment held the largest share in the Catharanthine Marketin 2020 and is growing at a CAGR of 4.4% during 2021-2026.Catharanthine sulfate is a vinblastine-type alkaloid precursor with antitumor activity. It inhibits AChR (Acetylcholine Receptor) by ion channel blocking and desensitization. Whie, Catharanthine tartrate is a precursor for synthesis of Vinblastine and Vincristine. Vincristine is more neurotoxic than vinblastine. Vinblastine and other vinca alkaloids are cell cycle-specific antitumor agents. The drug specifically binds to tubulin and blocks the ability of tubulin to polymerize into microtubules, leading to arrest of cell division in metaphase. Without proper chromosomal segregation during mitosis, cell death presumably occurs. Vincristine is one of the most commonly used pediatric chemotherapeutic agents and is used to treat both hematologic malignancies and solid tumors. It is a natural alkaloid that interferes with the assembly of microtubule structures leading to cell apoptosis. Due to the crucial role of Catharane sulphate and catharanthine tartrate in catharanthine market, it is projected to grow in the forecast period.

Catharanthine Market Segment Analysis - By Application

Pharmaceutical segment held the largest share in the Catharanthine Market in 2020 and is growing at a CAGR of 7.6% during 2021-2026.The most important indole alkaloids, VLB(Vinblastine ) and VCR(Vincristine), are clinically useful anticancer agents. Vinblastine is administered systemically in the treatment of leukemias, lymphomas, and testicular cancer. Vinblastine administered IL has been used for the treatment of KS. It is also used in treatment of non-Hodgkin lymphoma and is an active agent in the treatment of breast cancer. Vincristine is one of the most commonly used pediatric chemotherapeutic agents and is used to treat both hematologic malignancies and solid tumors. According to International Agency for Research on Cancer, an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths occurred in 2020 globally. One in five people develop cancer during their lifetime, and 1 in 8 men and 1 in 11 women die from the disease. These new estimates suggest that more than 50 million people are living within five years of a past cancer diagnosis. Hence the concerning cancer cases and deaths around the world increase the demand for Catharanthine market in the forecast period.

Catharanthine Market Segment Analysis – By Geography

North America region held the largest share in the Catharanthine Market in 2020 up to 52%, owing to the rising chronic disease patients such as cancer, tumor in the region. According to Internal Journal of Environmental Research and Public Health, the pharmaceutical market worldwide has significantly increased. In 2019, the value of the market was on the order of USD 1.25 trillion. The E7 countries such as Brazil, China, India, Indonesia, Mexico, Russia and Turkey accounting for one fifth of global pharmaceutical sales. According to IQVIA, Brand spending in developed markets will increase by $298 billion in the 5 years to 2020 driven by new products and price increases primarily in the U.S., China's pharmaceutical market has been constantly growing in recent years, and is estimated to reach US$161.8 billion by 2023, taking a 30% share of the global market. China is the world's second-largest pharmaceutical market followed by India. China's pharmaceutical market has been constantly growing in recent years, it will reach US$160-US$190 billion in spending. According to IQVIA, the Pharmaceutical industry in India is the 3rd largest in the world in terms of volume and14th largest in terms of value. According to Make in India, The Pharmaceutical sector currently contributes to around 1.72% of the country’s GDP. Pharmaceuticals industry expected to reach US$ 65 billion by 2024, and US$ 120-130 billion by 2030.Due to huge investment in Pharmaceutical industry the Catharanthine Market is projected to grow in the forecast period.

Inquiry Before Buying @ https://www.industryarc.com/reports/request-quote?id=15679

Catharanthine Market Drivers

Rising Per capita spending on Healthcare globally :

According to OECD (Organization for Economic Co-operation and Development) Health statistics, In 2019, per capita health spending in the U.S. exceededUS$10,000, more than two times higher than in Australia, France, Canada, New Zealand, and the U.K. Public spending. In the U.S., per-capital spending on private health insurance premiums, is higher than in any of the countries at $4,092 per capita, U.S. private spending is more than five times higher than Canada, the second-highest spender. In Sweden and Norway, private spending made up less than $100 per capita. As a share of total spending, private spending is much larger in the U.S. (40%) than in any other country (0.3%–15%).The average U.S. resident paid US$1,122 out-of-pocket for health care. The residents of France and New Zealand pay less than half of what Americans spend. Hence the increasing per capita spending on Healthcare will boost the Catharanthine Market in the forecast period.

Rising cancer Patients:

According to IARC(International Agency for Cancer and Research) Globocan 2020 new estimates shows that global cancer burden has risen to 19.3 million cases and 10 million cancer deaths in 2020.According to National Cancer Institute, an estimated 1,806,590 new cases of cancer was diagnosed in the United States and 606,520 people died from the disease. As of January 2019, there were an estimated 16.9 million cancer survivors in the United States. The number of cancer survivors is projected to increase to 22.2 million by 2030.Approximately 39.5% of men and women will be diagnosed with cancer at some point during their lifetime. National costs for cancer care were estimated to be US$208.9 billion in 2020 an increase of 10 % from previous years that is only due to the aging and growth of the U.S. population. Due to the medicinal use of Catharanthine in Cancer disease, the market is going to grow in the forecast period.

Catharanthine Market Challenges

High manufacturing cost of Catharanthine:

In the process of Catharanthine preparation, 1 kg of Vincristine has a cost of US$ 3.5 million, while Vinblastine has a cost of US$1 million. Half a ton of dry leaves of Catharanthus roseus are needed for the obtaining 1 g of vinblastine while to produce 1 kg of vincristine 530 kg are used. Besides, their extraction is very complicated since it is carried out in the presence of 200 molecules with similar chemical and physical properties. Therefore, 530 kg of dry leaves are necessary to produce 1 kg of Vincristine. The high cost is due to the low concentrations in the aerial portion. Due to the high market price, it can act as a restraining factor in the Catharanthine Market.

Catharanthine Market Landscape

Technology launches, acquisitions, and R&D activities are key strategies adopted by players in the Catharanthine Market. Catharanthine Market top companies are AK Scientific Inc, Stanford Chemicals, Cayman Chemicals, Bio Vision Inc, Enzo Biochem Inc, Hainan Yueyang Biotech Co Ltd, Abcam and ChemFaces.

Key Takeaways

North America dominates the Catharanthine Market, owing to the increasing contribution and maximum share in the global pharmaceutical industry. This is typically due to the prominent role of US pharmaceutical sector. 

Asia Pacific is also expected to demonstrate highest growth rate in the global catharanthine market. This is basically due to the growing pharmaceutical industry in emerging economies such as India and China.

In the United States, colorectal cancer and lung cancer, Breast cancer are among the most rapidly increasing cancers in younger populations and represent the most common cancers in men and women, respectively, between ages 18 and 49. 

It is important to build on this situation, in order to improve prevention, detection, and treatment of cancers in this population. Hence Catharanthine being vastly used in various cancer treatment medication has huge potential to grow in the forecast period.

Related Reports 

A.Coating Resins Market

https://www.industryarc.com/Report/11680/coating-resins-market.html

B.Facades Market

https://www.industryarc.com/Report/18421/facades-market-research-report-analysis.html

For more Chemicals and Materials Market reports, please click here